Visudyne fails occult AMD trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
QLT/Novartis' photodynamic therapy Visudyne (verteporfin) fails to show a clinical benefit after two years in the firms' Phase III VIO (Visudyne in Occult) trial. VIO, part of a series of trials looking at the agent's use in predominantly occult choroidal neovascularization (CNV), was designed to assess whether Visudyne can reduce vision loss in wet age-related macular degeneration patients with subfoveal occult with no classic CNV. "Two earlier trials, VIP (Visudyne in Photodynamic Therapy) and VIM (Visudyne in Minimally Classic)," showed efficacy in this population, QLT said. Visudyne currently is indicated for predominantly classic AMD...
You may also be interested in...
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.